Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts ASRT Hot Sheet
Join SI Premium – FREE
Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.7 million versus the consensus estimate of $28.87 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades NetApp (NTAP) to Outperform, Adds to Tactical Outperform List
- Gogoro adds three directors, expanding board to seven members
- Gogoro raises $61.8M in second equity round at $2.48 per share
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
